Ashwagandha For Thyroid Function Researches

Reviewed against current clinical literature | Updated 2025

---

Table of Contents

1. What Is Ashwagandha and Why Does It Matter for the Thyroid?
2. How Ashwagandha Affects TSH, T3, and T4 Levels
3. The Key Clinical Research: What Studies Actually Show
4. KSM-66 Thyroid Studies: The Standardized Extract Evidence
5. Ashwagandha for Hypothyroidism and Subclinical Hypothyroidism
6. Can Ashwagandha Worsen Hyperthyroidism or Graves' Disease?
7. Withanolides: The Active Compounds Driving Thyroid Effects
8. Safety Concerns: Thyrotoxicosis and Painless Thyroiditis
9. Ashwagandha and Thyroid Medications: Interaction Risks
10. Dosage, Timing, and Practical Guidance
11. Who Should Avoid Ashwagandha for Thyroid Support?
12. The Bottom Line: What the Research Tells Us in 2025

---

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. If you have a thyroid condition or are taking thyroid medication, consult a qualified healthcare provider before supplementing with ashwagandha.

---

What Is Ashwagandha and Why Does It Matter for the Thyroid?

Ashwagandha (Withania somnifera) has been used in Ayurvedic medicine for over 3,000 years, primarily valued as an adaptogen — a plant compound that helps the body resist physiological and psychological stress. In recent years, growing interest in natural approaches to hormonal health has brought ashwagandha thyroid research into the mainstream spotlight.

But why would a stress-regulating herb have any meaningful effect on thyroid function in the first place?

The answer lies in the well-documented relationship between the stress response system and the thyroid axis. Chronic stress elevates cortisol, which suppresses the hypothalamus–pituitary–thyroid (HPT) axis, ultimately reducing the production of the thyroid hormones triiodothyronine (T3) and thyroxine (T4) while dysregulating thyroid-stimulating hormone (TSH). Because ashwagandha helps modulate cortisol and the broader neuroendocrine stress response, researchers reasoned it might indirectly — and possibly directly — support thyroid hormone balance.

Over the past two decades, this hypothesis has been tested in animal models, small human trials, and reviewed in a growing body of literature. The findings are modest but genuinely interesting, particularly for people dealing with subclinical thyroid dysfunction.

This deep dive into ashwagandha for thyroid function research examines all available evidence honestly — including the benefits, the limitations, and the real safety concerns that deserve attention.

---

---

How Ashwagandha Affects TSH, T3, and T4 Levels

To understand how ashwagandha works on the thyroid, it helps to first understand the feedback loop that governs thyroid hormone production.

The hypothalamus releases thyrotropin-releasing hormone (TRH), which signals the pituitary gland to release TSH. TSH then stimulates the thyroid gland to produce T3 and T4. When T3 and T4 levels are adequate, they send a negative feedback signal back to the hypothalamus and pituitary, reducing TRH and TSH output. When thyroid hormones are low — as in hypothyroidism — TSH levels rise as the pituitary tries to drive more production from the thyroid gland.

Ashwagandha TSH dynamics appear to operate through several mechanisms:

1. Direct stimulation of thyroidal secretory activity: Bioactive compounds in ashwagandha, particularly withanolides, appear to directly stimulate thyroid tissue to increase T3 and T4 output.

1. HPT axis modulation: By increasing circulating T3 and T4 levels, ashwagandha subsequently reduces TSH via normal negative feedback. The result is a measurable decrease in TSH alongside increases in free T3 and T4.

1. Cortisol-mediated indirect pathway: By reducing chronic stress-related cortisol elevation, ashwagandha may relieve suppression of the HPT axis, allowing thyroid hormone production to normalize.

1. Antioxidant protection of thyroid tissue: Research suggests ashwagandha enhances antiperoxidation in hepatic and potentially thyroid tissue, protecting the gland from oxidative damage that can impair hormone synthesis.

The net effect on ashwagandha T3 T4 levels, as shown in human trials, is a meaningful increase in both hormones alongside a reduction in TSH — an outcome profile that is particularly relevant for people with elevated TSH and low-normal thyroid hormones.

---

The Key Clinical Research: What Studies Actually Show

The Landmark 2018 Human Trial

The most rigorous and widely cited piece of ashwagandha thyroid research to date is a double-blind, placebo-controlled trial published in 2018. Here is what the study involved and found:

• Design: Double-blind, randomized, placebo-controlled
• Participants: 50 patients with mild hypothyroidism (baseline TSH between 4.5 and 10 mIU/L)
• Intervention: 600 mg/day of ashwagandha root extract for 8 weeks
• Outcome: Statistically significant improvements across all three major thyroid markers

The results after 8 weeks were striking for a single-ingredient supplement study:

| Thyroid Marker | Change After 8 Weeks | |----------------|----------------------| | TSH | ↓ 17.4% | | T4 (thyroxine) | ↑ 19.6% | | T3 (triiodothyronine) | ↑ 41.5% |

Importantly, improvements began appearing at the 4-week assessment point and continued to develop through week 8, suggesting a gradual, progressive mechanism rather than an acute hormonal spike. This time course is consistent with adaptogenic activity rather than a direct pharmacological override of the thyroid axis.

This trial remains the primary evidence base for claims about ashwagandha's benefits for thyroid function. No subsequent randomized controlled trials of similar or greater size have been published as of mid-2025.

The 1997 Animal Study

An earlier 1997 rat study provided mechanistic underpinning for later human research. Investigators administering ashwagandha root extract to rodents observed stimulated thyroidal activity alongside enhanced antiperoxidation of hepatic tissue. These findings indicated that ashwagandha was directly promoting thyroid hormone production, not merely modulating TSH through downstream signaling.

While animal data cannot be directly extrapolated to humans, this study established a plausible biological mechanism and helped justify later human trials.

The 2008 Small Human Study

A small placebo-controlled 8-week human study published in 2008 reported subtle increases in thyroxine (T4) in participants taking ashwagandha. Although the sample size limited strong conclusions, the study introduced an early caution: if T4 levels rise, there is at least a theoretical risk of hyperthyroid symptoms in susceptible individuals. The authors noted the importance of monitoring thyroid markers during supplementation.

The 2023 Comprehensive Review

A 2023 review titled "Can Ashwagandha Benefit the Endocrine System?", published in PubMed Central, synthesized the available evidence across multiple endocrine systems, including the thyroid. The review concluded that ashwagandha improves thyroid secretory function, consistently increasing T3 and T4 while lowering TSH across reviewed studies. Crucially, it also catalogued three documented case reports of thyrotoxicosis associated with ashwagandha use — a meaningful safety signal that the review authors highlighted as warranting caution, especially in those with pre-existing hyperthyroid tendencies.

The 2024 Painless Thyroiditis Case Report

A 2024 case report published in PubMed Central described a rare adverse event: a patient who developed painless thyroiditis following ashwagandha supplementation. Painless thyroiditis involves inflammation of the thyroid gland that disrupts normal hormone storage and release, causing a transient surge in thyroid hormones followed by a hypothyroid phase. This case reinforced the understanding that ashwagandha's effects on thyroid tissue can, in rare circumstances, go beyond simple hormonal modulation into triggering inflammatory responses.

---

KSM-66 Thyroid Studies: The Standardized Extract Evidence

Among the various ashwagandha extracts commercially available, KSM-66 thyroid research deserves specific attention because the 2018 landmark trial used this particular standardized root extract.

KSM-66 is a full-spectrum ashwagandha root extract standardized to a minimum of 5% withanolides — the key bioactive compounds believed responsible for most of the plant's pharmacological effects. Because withanolide content and bioavailability vary significantly between ashwagandha preparations, the KSM-66 thyroid study data provides a more reliable evidence basis than results extrapolated across all ashwagandha products.

Key features of the KSM-66 thyroid evidence:

• The 600 mg/day dose used in the 2018 trial corresponds to the typical human dose range for KSM-66
• Standardization to withanolide content ensures consistent bioactive delivery
• KSM-66 has been studied more broadly than almost any other ashwagandha extract, with trials in stress, anxiety, testosterone, and now thyroid function

It is important to note, however, that the KSM-66 thyroid study is still a single trial with 50 participants. While the results are encouraging and statistically significant, independent replication in larger populations is needed before firm clinical recommendations can be made based on this extract specifically.

---

---

Ashwagandha for Hypothyroidism and Subclinical Hypothyroidism

This is arguably the question most people arrive with: Can ashwagandha actually help someone with hypothyroidism?

The honest answer is: it shows genuine promise for subclinical hypothyroidism, but the evidence for overt clinical hypothyroidism is much less developed.

What Is Subclinical Hypothyroidism?

Ashwagandha subclinical hypothyroid research is specifically relevant here because the 2018 trial enrolled patients who were subclinically hypothyroid — meaning their TSH was elevated (between 4.5 and 10 mIU/L) but not severely so, and they had not yet been prescribed thyroid replacement medication. Subclinical hypothyroidism is actually quite common, estimated to affect 3–8% of the general population, with symptoms that can include fatigue, mild weight gain, brain fog, and mood changes.

For this population, the 2018 trial data suggests ashwagandha may offer clinically meaningful normalization of thyroid markers without the need for pharmaceutical intervention. The 41.5% increase in T3, 19.6% rise in T4, and 17.4% TSH reduction observed are not trivial numbers in the context of subclinical dysfunction.

Ashwagandha and Hypothyroidism: Important Distinctions

For ashwagandha hypothyroid applications, several distinctions matter:

Subclinical hypothyroidism (TSH 4.5–10 mIU/L, normal T4): This is where the existing evidence applies directly. Ashwagandha may support normalization of the HPT axis without the risks associated with high-dose thyroid hormone replacement.

Overt hypothyroidism (TSH >10 mIU/L, low T4): There is no clinical trial evidence specifically in this population. Individuals with overt hypothyroidism typically require prescription thyroid hormone replacement, and ashwagandha should not be considered a substitute.

Hashimoto's thyroiditis (autoimmune hypothyroidism): This is a particularly nuanced case. Hashimoto's is an autoimmune condition in which the immune system attacks thyroid tissue. While ashwagandha's anti-inflammatory and potentially immunomodulatory properties are theoretically relevant, there are no dedicated trials in Hashimoto's patients. Some practitioners worry that immune modulation could theoretically affect autoimmune activity in unpredictable ways, though this remains speculative. Anyone with Hashimoto's should discuss supplementation with their endocrinologist.

Common Reader Question: Does Ashwagandha Replace Thyroid Medication?

No. Based on current evidence, ashwagandha should not replace prescription thyroid hormone therapy (such as levothyroxine) in people with diagnosed hypothyroidism who are under medical treatment. Its most plausible role is as a supportive intervention in subclinical cases or as an adjunct to discuss with a physician for those already managing hypothyroid symptoms through lifestyle.

---

Can Ashwagandha Worsen Hyperthyroidism or Graves' Disease?

This is where the safety calculus of ashwagandha thyroid function support shifts significantly.

The same mechanism that makes ashwagandha potentially beneficial for hypothyroid individuals — stimulating T3 and T4 production — makes it potentially dangerous for those with hyperthyroidism.

Hyperthyroidism occurs when the thyroid already produces too much hormone. Graves' disease, the most common cause, involves autoimmune stimulation of the thyroid that drives excessive T3 and T4 output. In this context, adding a supplement that further stimulates thyroidal secretory activity could push already-elevated thyroid hormones higher, worsening symptoms such as:

• Rapid or irregular heartbeat (palpitations, atrial fibrillation)
• Anxiety and tremor
• Unexplained weight loss
• Heat intolerance and excessive sweating
• Insomnia and restlessness

The three documented case reports of thyrotoxicosis associated with ashwagandha use — synthesized in the 2023 review — are particularly relevant here. Two occurred in previously healthy individuals taking high doses, and one occurred in a person with pre-existing hypothyroidism, suggesting that dose thresholds and individual susceptibility play a critical role.

People with hyperthyroidism, Graves' disease, or Plummer's disease should avoid ashwagandha thyroid supplementation unless directly supervised by an endocrinologist. This is not a theoretical precaution — it is grounded in documented adverse events.

---

Withanolides: The Active Compounds Driving Thyroid Effects

Understanding the withanolide thyroid connection helps explain both why ashwagandha works and why dosage precision matters.

Withanolides are a class of naturally occurring steroidal lactones found in Withania somnifera, particularly concentrated in the root. They are the primary bioactive constituents responsible for most of ashwagandha's pharmacological properties, including its adaptogenic, anti-inflammatory, and hormone-modulating effects.

How Withanolides Affect Thyroid Tissue

Withanolide thyroid activity appears to operate through several pathways:

1. Direct thyrocyte stimulation: Withanolides may directly interact with thyroid gland cells (thyrocytes) to enhance hormone biosynthesis and secretion, independent of TSH signaling.

1. HPT axis modulation: By influencing glucocorticoid receptors and the stress-response cascade, withanolides modulate the upstream hormonal environment that governs TSH release.

1. Anti-inflammatory and antioxidant effects: Oxidative stress damages thyroid tissue and impairs enzyme function in hormone synthesis. Withanolides' antioxidant properties may protect thyroid cells, supporting more efficient T3 and T4 production.

1. NF-κB pathway inhibition: Some withanolides inhibit the NF-κB inflammatory signaling pathway. Since chronic inflammation can suppress thyroid function, this mechanism may contribute indirectly to improved thyroid hormone levels.

Why Withanolide Concentration Matters

Because withanolide content varies widely between ashwagandha products — from less than 1% in raw root powder to 5–10% in standardized extracts — the thyroid effects observed in clinical research may not generalize to low-quality or poorly standardized supplements. This is why the standardization of KSM-66 to ≥5% withanolides is clinically meaningful when interpreting the 2018 trial results.

---

Safety Concerns: Thyrotoxicosis and Painless Thyroiditis

The ashwagandha thyroid research landscape includes not just efficacy data but important safety signals that any balanced analysis must address directly.

Thyrotoxicosis: Documented Case Reports

Thyrotoxicosis is a clinical state caused by excess thyroid hormone in the body, whether from overproduction or from tissue destruction releasing stored hormone. Symptoms include tachycardia, weight loss, tremor, heat sensitivity, and in severe cases, thyroid storm — a life-threatening emergency.

Three case reports of thyrotoxicosis associated with ashwagandha have been documented in the medical literature:

• Two cases occurred in previously healthy individuals who developed hyperthyroid symptoms after beginning ashwagandha supplementation
• One case occurred in a hypothyroid patient who was already on thyroid management

The most detailed of these cases involved a 62-year-old who developed thyrotoxicosis after taking 1,950 mg/day of ashwagandha root extract for approximately two months. This dose is substantially higher than the 600 mg/day used in the 2018 efficacy trial — approximately 3.25 times higher — underscoring the importance of not exceeding recommended doses.

While three case reports in the context of widespread global ashwagandha use represents a low absolute incidence, the severity of thyrotoxicosis means the risk cannot be dismissed. It warrants monitoring and dose-appropriate use.

Painless Thyroiditis: The 2024 Case Report

The 2024 case report describing ashwagandha-associated painless thyroiditis introduced a previously uncharacterized adverse effect. Painless thyroiditis (also called silent thyroiditis) is an inflammatory disruption of the thyroid that can cause:

• An initial hyperthyroid phase (as stored hormone leaks from inflamed gland)
• Followed by a hypothyroid phase as the gland recovers
• Eventually, in most cases, return to normal function

This case suggests that ashwagandha's effects on thyroid tissue can in rare instances trigger inflammatory responses rather than simply modulating hormone secretion. The mechanism is not fully understood but may involve immune activation within thyroid tissue.

Monitoring Recommendations

Given these safety signals, anyone using ashwagandha for thyroid support should consider:

• Baseline thyroid panel before starting: TSH, free T3, free T4
• Follow-up testing at 8–12 weeks: To monitor for unexpected elevation in T3/T4 or thyrotoxic symptoms
• Symptom awareness: Palpitations, unexplained weight loss, excessive sweating, tremor, or anxiety should prompt immediate medical evaluation
• Dose adherence: Staying within the studied range (600 mg/day for KSM-66) rather than self-escalating

---

---

Ashwagandha and Thyroid Medications: Interaction Risks

One of the most common and important questions in ashwagandha thyroid function discussions is whether it interacts with thyroid medications. This is a legitimate concern that deserves a direct answer.

Levothyroxine (Synthroid, Eltroxin)

Levothyroxine is a synthetic T4 replacement used for overt hypothyroidism and Hashimoto's thyroiditis. The primary theoretical concern is:

Additive effect: If ashwagandha increases endogenous T4 production and the patient is simultaneously taking levothyroxine, total T4 levels could become supraphysiological, potentially causing hyperthyroid symptoms or thyrotoxicosis.

This has not been formally studied in a controlled drug-herb interaction trial, but the 2018 study population excluded people on thyroid medications precisely because of this concern. Until dedicated interaction studies exist, people on levothyroxine should consult their prescribing physician before adding ashwagandha.

Methimazole and Propylthiouracil (Antithyroid Drugs)

These medications are used to reduce thyroid hormone production in hyperthyroidism. Since ashwagandha appears to stimulate thyroid hormone production, it could theoretically work in direct opposition to these medications, reducing their efficacy. This is another situation where co-use is not recommended without medical supervision.

Thyroid Hormone Absorption Considerations

Some supplements and foods affect levothyroxine absorption when taken concurrently. While ashwagandha is not specifically documented to impair absorption, it is generally advisable to take thyroid medications separately from supplements as a precautionary measure — the standard guidance is to take levothyroxine on an empty stomach, 30–60 minutes before any food or supplements.

---

Dosage, Timing, and Practical Guidance

Based on available ashwagandha thyroid research, here is what the evidence suggests regarding practical use:

Evidence-Based Dosage

The only well-controlled human trial showing thyroid benefits used:

• 600 mg/day of standardized ashwagandha root extract (KSM-66)
• Split into two doses or as a single daily dose
• Duration: Minimum 8 weeks, with effects beginning around week 4

There is no clinical evidence supporting higher doses for greater thyroid benefit, and the thyrotoxicosis case reports involved doses up to 1,950 mg/day — suggesting a clear risk signal at high doses.

How Long Does It Take to Work?

The 2018 trial showed that thyroid improvements began at the 4-week mark and continued to develop through week 8. This is consistent with ashwagandha's adaptogenic profile — effects build gradually rather than manifesting acutely. Expecting results in under a month is unrealistic based on current data.

Form and Standardization

Not all ashwagandha products are created equal for thyroid applications:

• Root extract standardized to ≥5% withanolides (such as KSM-66 or Sensoril) is most aligned with clinical trial data
• Raw root powder has lower and inconsistent withanolide content
• Leaf extracts have a different withanolide profile than root extracts and have not been studied specifically for thyroid effects

Timing of Doses

No specific timing protocol has been established for thyroid-related applications. General guidance includes:

• Taking with food to reduce potential gastrointestinal discomfort
• If taking thyroid medications, maintaining clear separation between medication and supplement intake
• Consistent daily use is more important than specific time-of-day optimization

---

Who Should Avoid Ashwagandha for Thyroid Support?

Based on current evidence, the following groups should either avoid ashwagandha for thyroid purposes or proceed only under direct medical supervision:

Clear contraindications:

• People with hyperthyroidism (any cause, including Graves' disease, toxic adenoma, or Plummer's disease)
• People with thyroid cancer or history thereof
• People taking antithyroid medications (methimazole, propylthiouracil)

Proceed only with medical supervision:

• People taking levothyroxine or other thyroid hormone replacement
• People with Hashimoto's thyroiditis (due to immunomodulatory uncertainty)
• People with autoimmune conditions generally (ashwagandha's immune effects are bidirectional and context-dependent)
• Pregnant women (ashwagandha has uterotonic properties and should be avoided in pregnancy)
• People with liver conditions (rare hepatotoxicity reports exist for high-dose ashwagandha)

Consider caution:

• Anyone with palpitations or cardiac arrhythmias (thyroid hormone elevation can exacerbate these)
• People with anxiety disorders — while ashwagandha typically reduces anxiety, hyperthyroid-like effects at higher doses could theoretically worsen it

---

The Bottom Line: What the Research Tells Us in 2025

After reviewing all available ashwagandha thyroid research, here is an honest summary of where the evidence stands:

What We Know With Reasonable Confidence

1. The 2018 double-blind trial is genuinely encouraging for subclinical hypothyroidism: A 17.4% reduction in TSH, 19.6% increase in T4, and 41.5% increase in T3 over 8 weeks in a 50-patient RCT is clinically meaningful for a single supplement intervention. This is the strongest piece of data we have.

1. The mechanism is biologically plausible: Withanolides stimulate thyroidal secretory activity and modulate the HPT axis through multiple pathways, as supported by both animal and human research.

1. KSM-66 is the best-evidenced form: The standardized extract used in the landmark trial provides more reliable withanolide delivery than unstandardized products.

1. Safety risks are real but manageable with appropriate use: Three thyrotoxicosis cases and one painless thyroiditis case are documented. These occurred predominantly at high doses or in susceptible individuals. At 600 mg/day with baseline and follow-up monitoring, risk appears manageable for subclinical hypothyroid populations.

What Remains Uncertain

1. The evidence base is thin: One human trial of 50 patients, published in 2018, remains the sole RCT. No new clinical trials have been published between 2024 and mid-2025. The field needs larger, independently replicated studies.

1. Hashimoto's and overt hypothyroidism: There are no trials in these populations. Clinical extrapolation from the subclinical hypothyroid trial is not evidence-based.

1. Long-term effects are unknown: The 2018 trial ran for only 8 weeks. Whether benefits persist, diminish, or accumulate over months or years of use is unknown.

1. Drug interaction data is absent: The interaction profile with levothyroxine and antithyroid medications has never been formally studied.

Practical Takeaway

Ashwagandha, specifically as KSM-66 at 600 mg/day, represents a reasonable conversation to have with your doctor if you have subclinical hypothyroidism (TSH 4.5–10 mIU/L), are not currently on thyroid medication, and want to explore supportive options. It should not be used to replace medical management of diagnosed thyroid conditions, should be avoided in hyperthyroidism, and should be accompanied by baseline and follow-up thyroid testing.

The honest verdict on ashwagandha for thyroid function: promising but preliminary. The 2018 data is the most important thing in the field, and until larger trials replicate and expand on it, this remains a supplement with credible potential rather than established clinical protocol.

---

---

Frequently Asked Questions

Q: Can ashwagandha help with Hashimoto's disease? A: There are no clinical trials in Hashimoto's patients specifically. While ashwagandha's anti-inflammatory properties are theoretically interesting, anyone with Hashimoto's should consult their endocrinologist before use due to the potential immunomodulatory effects and the risk of compounding thyroid hormone levels if they are already being managed with levothyroxine.

Q: How does ashwagandha affect TSH, T3, and T4? A: Based on the 2018 clinical trial, 600 mg/day of standardized ashwagandha root extract over 8 weeks decreased TSH by 17.4%, increased T4 by 19.6%, and increased T3 by 41.5% in mild hypothyroid patients. These changes occur through direct thyroid stimulation and HPT axis modulation.

Q: Can ashwagandha interact with levothyroxine? A: This has not been formally studied. Theoretically, ashwagandha's T4-increasing effects could produce additive thyroid hormone elevation in someone already taking levothyroxine. Medical consultation before combining these is essential.

Q: What is the safe dosage for thyroid support? A: The only evidence-based dose for thyroid benefits is 600 mg/day of standardized ashwagandha root extract (as used in the 2018 trial). The thyrotoxicosis case involving 1,950 mg/day suggests dose escalation carries risk. Stick to 600 mg/day.

Q: How long does ashwagandha take to affect thyroid function? A: The 2018 trial showed improvements beginning at 4 weeks and continuing through 8 weeks of daily use. Do not expect results in under a month.

Q: Is there a risk of thyrotoxicosis from ashwagandha? A: Yes, though rare. Three cases have been documented in the medical literature, including one in a 62-year-old taking 1,950 mg/day. Risk appears dose-dependent and may be higher in those with underlying thyroid sensitivity. Monitoring thyroid levels and adhering to recommended doses reduces this risk.

---

This post references peer-reviewed clinical trial data, systematic reviews, and documented case reports. All statistics cited are drawn from published research as of mid-2025. This article does not constitute medical advice.